THE FIRST TREATMENT SPECIFICALLY
approved for adult patients with
KRAS-mutated recurrent LGSOC

The efficacy of AVMAPKI FAKZYNJA CO-PACK was evaluated in RAMP-201, an open-label, multicenter study that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC.

• Patients were required to have received at least one prior systemic therapy, including a platinum-based regimen.
• Median age of patients in the study was 60 years (range 29 to 87 years).
• 75% were White, 3.5% were Asian, 3.5% were Black or African American, and 18% did not have race reported; 
3.5% of patients were Hispanic or Latino.
• Fourteen percent of patients had received 1 prior line of systemic therapy, 25% of patients had received 
2 prior lines, 18% had received 3 prior lines and 40% had received more than 3 prior lines. All patients had received prior platinum-based chemotherapy.
• 84% received prior hormonal therapy (as maintenance or treatment), 40% received prior bevacizumab and 21% received a prior MEK inhibitor.
• Patients received AVMAPKI 3.2 mg orally twice weekly for the first 3 weeks out of a 4-week cycle and FAKZYNJA
200 mg orally twice daily for the first 3 weeks out of a 4-week cycle until disease progression or unacceptable toxicity.
• Patients were excluded if they were candidates for debulking surgery, were on treatment with warfarin, had an active skin disorder requiring systemic therapy within the past year, or had an ocular disorder (including a history of retinal pathology, an active or chronic visually significant corneal disorder, or a history of glaucoma).

Please read the Important Safety Information.